ACE2 and COVID-19: Although heparin is classically used as an anticoagulant, it has also been demonstrated to bind and reduce the activity of a range of cytokines implicated in the COVID‐19‐associated cytokine storm (Mulloy, Hogwood, Gray, Lever, & Page, 2015) and also interacts with the SARS‐CoV‐2 Spike protein in a manner which causes structural alteration of the ACE2‐binding domain which is likely to reduce viral entry (Mycroft‐West et al., 2020).